Patient Perception Study for AL-4943A

Alcon

Status and phase: Completed; Phase 4

Conditions: Allergic Conjunctivitis

Treatments: Drug: AL-4943A

Study type: Interventional

Funder types: Industry

Identifiers

NCT01294969

SMA-10-15

Details and patient eligibility

About

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Enrollment: 47 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of allergic conjunctivitis within last 24 months
• Active signs and symptoms of ocular allergies

Exclusion criteria

• Severe or serious ocular condition, ocular surgical intervention, ocular infection

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

47 participants in 1 patient group

AL-4943A

Experimental group

Description:

One drop per day in both eyes

Treatment:

Drug: AL-4943A